Rituximab, gemcitabine and oxaliplatin: An effective regimen in patients with refractory and relapsing mantle cell lymphoma

Leukemia and Lymphoma

Volumn 48, Issue 11, 2007, Pages 2172-2178

  Rodríguez, José ^a   Gutierrez, Antonio ^a   Palacios, Andres ^b   Navarrete, Mayda ^b   Blancas, Isabel ^c   Alarcón, Jesus ^a   Caballero, Maria ^d   De Mattos, Silvia Fernández ^e   Gines, Jordi ^a   Martínez, Jordi ^a   Lopez, Andres ^b  

^a HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^d HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^e UNIVERSITAT DE LES ILLES BALEARS   (Spain)

Author keywords

Gemcitabine; GEMOX R; Mantle cell lymphoma; Oxaliplatin; Rituximab; Treatment

Indexed keywords

GEMCITABINE; OXALIPLATIN; RITUXIMAB;

ADULT; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; INFECTION; MALE; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL RATE; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; RECURRENCE; SALVAGE THERAPY; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 36148944548     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701618268     Document Type: Article

References (31)

1. Evans, L. S. and Hancock, B. W. (2003) Non-Hodgkin lymphoma. Lancet, 362, pp. 139-146.
2. Witzig, T. E. (2005) Current treatment approaches for mantle-cell lymphoma. J Clin Oncol, 23, pp. 6409-6414.
3. Romaguera, J., Fayad, L., Rodriguez, M., Hagemeister, F. B., Pro, B. and McLaughlin, P. (2006) Blastoid mantle cell lymphoma (MCL): 5-yr failure-free survival (FFS) rate of 50%, without failures after 2.5 years following treatment with rituximab (R)-hyperCVAD alternating with R-methotrexate/cytarabine (M/A). Blood (Suppl.), 108, p. 2749.
4. Kiss, T. L., Mollee, P., Lazarus, H. M. and Lipton, J. H. (2005) Stem cell transplantation for mantle cell lymphoma: If, when and how?. Bone Marrow Transplant, 36, pp. 655-661.
5. Dumontet, C., Morschhauser, F., Solal-Celigny, P., Bouafia, F., Bourgeois, E. and Thieblemont, C. (2001) Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma. Br J Haematol, 113, pp. 772-778.
6. Savage, D. G., Rule, S. A., Tighe, M., Garrett, T. J., Oster, M. W. and Lee, R. T. (2000) Gemcitabine for relapsed or resistant lymphoma. Ann Oncol, 11, pp. 595-597.
7. Fossa, A., Santoro, A., Hiddemann, W., Truemper, L., Niederle, N. and Buksmaui, S. (1999) Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol, 17, pp. 3786-3792.
8. Bernell, P. and Ohm, L. (1998) Promising activity of gemcitabine in refractory high-grade non-Hodgkin's lymphoma. Br J Haematol, 101, pp. 203-204.
9. Germann, N., Brienza, S., Rotarski, M., Emile, J. F., Palma, M Di and Musset, M. (1999) Preliminary results on the activity of oxaliplatin (L-OHP) in refractory/recurrent non-Hodgkin's lymphoma patients. Ann Oncol, 10, pp. 351-354.
10. Berinstein, N. L. and Mangel, J. (2004) Integrating monoclonal antibodies into the management of mantle cell lymphoma. Semin Oncol, 31, pp. 2-6.
11. Sampol, A., Rodriguez, J., Galmes, B., Gutierrez, A. and Besalduch, J. (2004) Gemcitabine and oxaliplatinum: An effective regimen in a patient with progressive refractory mantle cell lymphoma. Leuk Lymphoma, 45, pp. 1289-1291.
12. A predictive model for aggressive non-Hodgkin's lymphoma (1993) The International Non-Hodgkin's Lymphoma Prognostic Factors project. N Engl J Med, 329, pp. 987-994.
13. Rodriguez, J., Cabanillas, F., McLaughlin, P., Swan, F., Rodriguez, M. and Hagemeister, F. (1992) A proposal for a simple staging system for intermediate grade lymphoma and immunoblastic lymphoma based on the 'tumor score'. Ann Oncol, 3, pp. 711-717.
14. Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I. and Connors, J. M. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol, 17, p. 1244.
15. Kaplan, E. and Meier, P. (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc, 53, pp. 457-481.
16. Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R. and Howard, S. V. (1977) Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer, 35, pp. 1-39.
17. Cox, D. R. (1972) Regression models and life-tables. J R Stat Soc, 34, p. 187.
18. Howard, O. M., Gribben, J. G., Neuberg, D. S., Grossbard, M., Poor, C. and Janicek, M. J. (2002) Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: Molecular complete responses are not predictive of progression-free survival. J Clin Oncol, 20, pp. 1288-1294.
19. Romaguera, J. E., Fayad, L., Rodriguez, M. A., Broglio, K. R., Hagemeister, F. B. and Pro, B. (2005) High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol, 23, pp. 7013-7023.
20. Mavroudis, D., Pappas, P., Kouroussis, C., Kakolyris, S., Agelaki, S. and Kalbakis, K. (2003) A dose-escalation and pharmacokinetic study of gemcitabine and oxaliplatin in patients with advanced solid tumors. Ann Oncol, 14, pp. 304-312.
21. Lorusso, P. M. (2000) Oxaliplatin in tumors other than colorectal cancer. Oncology (Williston Park), 14, pp. 33-37.
22. Corazzelli, G., Russo, F., Capobianco, G., Marcacci, G., Della Cioppa, P. and Pinto, A. (2006) Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study. Ann Oncol, 17, pp. iv18-iv24.
23. Oki, Y., McLaughlin, P., Pro, B., Hagemeister, F. B., Bleyer, A. and Loyer, E. (2005) Phase II study of oxaliplatin in patients with recurrent or refractory non-Hodgkin lymphoma. Cancer, 104, pp. 781-787.
24. Wenger, C., Stern, M., Herrmann, R., Rochlitz, C. and Pless, M. (2005) Rituximab plus gemcitabine: A therapeutic option for elderly or frail patients with aggressive non-Hodgkin's lymphoma?. Leuk Lymphoma, 46, pp. 71-75.
25. Chau, I., Webb, A., Cunningham, D., Hill, M., Rao, S. and Ageli, S. (2001) An oxaliplatin-based chemotherapy in patients with relapsed or refractory intermediate and high-grade non-Hodgkin's lymphoma. Br J Haematol, 115, pp. 786-792.
26. Morschhauser, F., Depil, S., Jourdan, E., Wetterwald, M., Bouabdallah, R. and Marit, G. (2007) Phase II study of gemcitabine-dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma. Ann Oncol, 18, pp. 370-375.
27. Gnaoui, T El, Dupuis, J., Belhadj, K., Jais, J., Rahmouni, A. and Copie-Bergman, C. (2007) Rituximab, gemcitabine and oxaliplatin: An effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. Ann Oncol, 18, pp. 1363-1368.
28. Marce, S., Molina-Arcas, M., Villamor, N., Casado, F. J., Campo, E. and Pastor-Anglada, M. (2006) Expression of human equilibrative nucleoside transporter 1 (hENT1) and its correlation with gemcitabine uptake and cytotoxicity in mantle cell lymphoma. Haematologica, 91, pp. 895-902.
29. Schaefer-Cutillo, J., Friedberg, J. W. and Fisher, R. I. (2007) Novel concepts in radioimmunotherapy for non-Hodgkin's lymphoma. Oncology (Williston Park), 21, pp. 203-212.
30. Rummel, M. J., Al-Batran, S. E., Kim, S. Z., Welslau, M., Hecker, R. and Kofahl-Krause, D. (2005) Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol, 23, pp. 3383-3389.
31. Forstpointner, R., Dreyling, M., Repp, R., Hermann, S., Hanel, A. and Metzner, B. (2004) The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood, 104, pp. 3064-3071.